Value of Intraoperative Radiotherapy in Locally Advanced Rectal Cancer

2006 ◽  
Vol 49 (9) ◽  
pp. 1257-1265 ◽  
Author(s):  
Floris T. J. Ferenschild ◽  
Maarten Vermaas ◽  
Joost J. M. E. Nuyttens ◽  
Wilfried J. Graveland ◽  
Andreas W. K. S. Marinelli ◽  
...  
2020 ◽  
Vol 15 (1) ◽  
Author(s):  
Sergey Potemin ◽  
Jens Kübler ◽  
Ivan Uvarov ◽  
Frederik Wenz ◽  
Frank Giordano

Abstract Background Neoadjuvant external-beam radiotherapy (EBRT) with concomitant chemotherapy is the current standard-of-care for locally-advanced rectal cancer. Intraoperative radiotherapy (IORT) is to date only recommended for pelvic recurrences or incompletely resectable tumors. We here report on patients with stage II/III rectal cancer that were treated with IORT in a regional Russian university center due to limited access to EBRT. Methods We retrospectively analyzed data from patients that were diagnosed with locally-advanced rectal cancer and underwent surgery from December 2012 to October 2016 at a regional oncological center in Russia (Krasnodar). During this period, access to EBRT was limited due to a temporary lack of a sufficient number of EBRT facilities. Patients unable to travel to a distant radiotherapy site received IORT alone, those that could travel received neoadjuvant external beam (chemo-) radiotherapy. Factors of interest were tumor stage, tumor differentiation, resection status, surgery type and neoadjuvant or adjuvant chemotherapy. We assessed local progression-free survival (L-PFS), PFS and overall survival (OS). Results A total of 172 patients were included in this analysis. Of those, 92 (53.5%) were treated with IORT alone (median dose: 15 Gy [8.4–17 Gy]) and 80 (46.5%) received both neoadjuvant EBRT (median dose: 50.4 Gy [40–50.4 Gy]) and IORT (median dose: 15 Gy [15–17 Gy]). The median age was 65 years [33–82]. The median follow-up was 23 months [0–63 months]. The incidence of toxicity was low in both groups with an overall complication rate of 5.4%. Local PFS at 4 years was comparable with 59.4% in the IORT group and 65.4% in the IORT/EBRT group (p = 0.70). Similarly, there was no difference in OS or PFS (p = 0.66, p = 0.51, respectively). Conclusions IORT is a valuable option for patients with locally-advanced rectal cancer in the absence of access to EBRT.


2021 ◽  
Author(s):  
Yu Guo ◽  
Shuang Wang ◽  
Zeyun Zhao ◽  
Wangsheng Xue ◽  
Jiannan Li ◽  
...  

Abstract Transanal total mesorectal excision (taTME) which aims to achieve more accurately complete resection of distal mesorectum has arouse much more attention worldwide. TaTME can significantly improve the local control (LC) and overall survival (OS) of the patients with locally advanced rectal cancer. Intraoperative radiotherapy (IORT), also as a emerging treatment method for locally advanced tumors, can lead to the potential for dose escalation, reduce overall treatment time, and increase patient convenience. Our study firstly combined taTME and IORT for the treatment of locally advanced rectal cancer. The tumor involved 60 mm rectal wall and located 30 mm from anal margin. TaTME and IORT were successfully achieved in this patient. There was no obvious complications occurred, including the anastomotic fistula. The patient recovered well and further systematic systematic chemotherapy and radiotherapy were suggested. We conclude that taTME with low-energy X-rays IORT may not only benefit the circumferential resection margin (CRM) but also improve the local control (LC) for the patient with locally advanced rectal cancer.


Sign in / Sign up

Export Citation Format

Share Document